Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

This non-binding resolution expresses the House of Representatives' view that the FDA should regulate mifepristone, a medication used for abortion, based on scientific evidence rather than political pressure. It highlights over 25 years of data showing the drug is safe and effective when prescribed via telemedicine or dispensed by mail and pharmacy. The bill advocates for policies that ensure equitable access to this care, particularly for marginalized communities facing barriers due to state-level restrictions. By citing numerous studies and medical organizations, the resolution calls for transparent, science-based decisions to maintain current access methods.